NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis $1.25 -0.06 (-4.58%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.4050-Day Range$1.24▼$2.0452-Week Range$0.53▼$2.84Volume20,539 shsAverage Volume110,811 shsMarket Capitalization$68.88 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Connect Biopharma alerts: Email Address Connect Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside420.0% Upside$6.50 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.54 to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.48 out of 5 starsMedical Sector304th out of 936 stocksPharmaceutical Preparations Industry141st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingConnect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageConnect Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Connect Biopharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently decreased by 30.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTB. Previous Next 3.0 News and Social Media Coverage News SentimentConnect Biopharma has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Connect Biopharma this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Connect Biopharma are expected to decrease in the coming year, from $0.54 to ($0.63) per share.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Connect Biopharma Stock (NASDAQ:CNTB)Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Read More CNTB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTB Stock News HeadlinesJuly 1, 2024 | globenewswire.comConnect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics ForumJune 12, 2024 | globenewswire.comConnect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 12, 2024 | globenewswire.comConnect Biopharma Announces New Leadership and Chair of the Board of DirectorsMay 22, 2024 | globenewswire.comConnect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe AsthmaMay 7, 2024 | globenewswire.comConnect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe AsthmaApril 26, 2024 | finance.yahoo.comConnect Biopharma Holdings Limited (CNTB)April 17, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 16, 2024 | globenewswire.comConnect Biopharma Reports Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic PartnershipsApril 7, 2024 | marketwatch.comADRs Advance; Connect Biopharma Climbs 19%April 1, 2024 | marketwatch.comADRs End Higher; Connect Biopharma Climbs 26%March 19, 2024 | tmcnet.comConnect Biopharma to Participate in H.C. Wainwright 2n? Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 19, 2024 | globenewswire.comConnect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 5, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Connect Biopharma Holdings Limited - Depositary Receipt () (CNTB) with Buy RecommendationFebruary 22, 2024 | benzinga.comConnect Biopharma Hldgs Stock (NASDAQ:CNTB) Dividends: History, Yield and DatesFebruary 12, 2024 | finance.yahoo.comConnect Biopharma Appoints Industry Veteran James Huang to Board of DirectorsSee More Headlines Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTB CUSIPN/A CIK1835268 Webwww.connectbiopharm.com Phone18587271045Fax+1 8586147007Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+420.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.99 Quick Ratio4.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.68Miscellaneous Outstanding Shares55,100,000Free Float42,650,000Market Cap$68.88 million OptionableOptionable Beta-0.39 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Wubin Pan M.B.A. (Age 59)Ph.D., Co-Founder, President & Chairman of the Board of Directors Dr. Zheng Wei Ph.D. (Age 60)Co-Founder, CEO & Director Mr. Steven Chan (Age 52)Chief Financial Officer Mr. Jiang Bian J.D.General Counsel & Chief Compliance OfficerDr. Lei Sun Ph.D. (Age 60)VP of Biologics & Head of CMC Dr. Raul Collazo Ph.D.VP & Global Head of Medical AffairsDr. Malinda V. Longphre Ph.D.VP & Head of US Clinical OperationsMore ExecutivesKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTZentalis PharmaceuticalsNASDAQ:ZNTLNektar TherapeuticsNASDAQ:NKTRCorMedixNASDAQ:CRMDZevra TherapeuticsNASDAQ:ZVRAView All CompetitorsInstitutional OwnershipKeudell Morrison Wealth ManagementBought 12,500 shares on 7/17/2024Ownership: 0.058%Keudell Morrison Wealth ManagementBought 8,500 shares on 5/7/2024Ownership: 0.036%View All Institutional Transactions CNTB Stock Analysis - Frequently Asked Questions How have CNTB shares performed this year? Connect Biopharma's stock was trading at $1.18 at the beginning of the year. Since then, CNTB stock has increased by 5.9% and is now trading at $1.25. View the best growth stocks for 2024 here. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $150 million in an initial public offering on Friday, March 19th 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO. Who are Connect Biopharma's major shareholders? Connect Biopharma's top institutional investors include Keudell Morrison Wealth Management (0.06%). How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
